NASDAQ:AKBA - Akebia Therapeutics Stock Price, Forecast & News

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Akebia Therapeutics Inc (NASDAQ:AKBA) released its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.09. The biopharmaceutical company had revenue of $91.98 million for the quarter, compared to analysts' expectations of $93.94 million. Akebia Therapeutics had a negative return on equity of 32.74% and a negative net margin of 75.39%. View Akebia Therapeutics' Earnings History.

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Akebia Therapeutics.

5 brokers have issued 12-month price objectives for Akebia Therapeutics' stock. Their forecasts range from $9.00 to $16.00. On average, they anticipate Akebia Therapeutics' stock price to reach $13.80 in the next year. This suggests a possible upside of 38.1% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.

Media headlines about AKBA stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Akebia Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Akebia Therapeutics.

Akebia Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 9,340,000 shares, a drop of 5.1% from the January 15th total of 9,840,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the days-to-cover ratio is currently 6.3 days. Approximately 8.8% of the shares of the stock are short sold. View Akebia Therapeutics' Current Options Chain.

Some companies that are related to Akebia Therapeutics include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), PTC Therapeutics (PTCT) and Emergent Biosolutions (EBS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHK), Gilead Sciences (GILD), FireEye (FEYE), TherapeuticsMD (TXMD), Energy Transfer LP Unit (ET), Corbus Pharmaceuticals (CRBP), AbbVie (ABBV), Bank of America (BAC) and Flexion Therapeutics (FLXN).

Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baupost Group LLC MA (16.45%), State Street Corp (2.89%), Point72 Asset Management L.P. (1.98%), Geode Capital Management LLC (1.39%), Rice Hall James & Associates LLC (1.18%) and Goldman Sachs Group Inc. (0.63%). Company insiders that own Akebia Therapeutics stock include John P Butler, Steven C Gilman and Steven Keith Burke. View Institutional Ownership Trends for Akebia Therapeutics.

AKBA stock was sold by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, State Street Corp, UBS Group AG, Old West Investment Management LLC, Rice Hall James & Associates LLC, Rafferty Asset Management LLC, Boston Partners and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Akebia Therapeutics.

AKBA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., AQR Capital Management LLC, Russell Investments Group Ltd., Renaissance Technologies LLC, California Public Employees Retirement System and Geode Capital Management LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman and Steven Keith Burke. View Insider Buying and Selling for Akebia Therapeutics.

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKBA stock can currently be purchased for approximately $9.99.

Akebia Therapeutics has a market capitalization of $1.19 billion and generates $207.74 million in revenue each year. The biopharmaceutical company earns $-143,590,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.View Additional Information About Akebia Therapeutics.

The official website for Akebia Therapeutics is http://www.akebia.com/.

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]